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Adenovirus (AdV) vectors are commonly used in cancer gene therapy trials, evaluated in gene therapy and used 
as vaccines for various diseases. AdV vectors are well studied and are suitable as vaccine vectors due to their 
ability to infect different cell types, remain episomal and produce stable high titer material. Manufacturing of safe 
and efficacious clinical-grade virus relies on a scalable and cost-effective production process. In this study, we 
have combined experimental work and process economy calculations, from AdV production in cell culture to 
purified bulk product up to 10L scale. An efficient and scalable process for AdV production was developed by 
evaluation of each process step. The most studied vector is serotype 5, making this a suitable system for 
process development of AdV vectors. Human AdV5 expressing the green fluorescent protein (GFP) was used 
for process development. First, suspension HEK 293 cells adapted to serum-free cell culture medium were 
optimized for AdV production and evaluated in different single use bioreactor systems. Tween 20 was used for 
cell lysis as a replacement for the traditionally used Triton X-100 (now on the Authorization list (Annex XIV) of 
REACH, the regulation on Registration, Evaluation, Authorization and restriction of Chemicals). A residual 
Tween 20 assay with low detection limit was set-up. Filters and conditions for clarification, concentration and 
buffer exchange by tangential flow filtration were optimized. Anion exchange based capture step alternatives 
were compared, including different chromatography resins and membrane formats. Finally, core bead 
technology was evaluated as an alternative to size exclusion chromatography for the polishing step before the 
final formulation. Analytical methods for virus titer are challenging and depend on purity and quality of the 
sample. For total virus titer, qPCR and HPLC methods were used. Furthermore, a method based on surface 
plasmon resonance (Biacore) was developed for analysis of adenovirus titer. For infectious virus titer, we have 
used a cell based assay with automatic image analysis. Based on analytical data different downstream process 
alternatives were compared regarding load capacity, recovery and purity and we propose a robust and scalable 








Figure 1 – Size exclusion HPLC analysis of start clarified material 
and final purified sample from the selected process variant. 
